&nbsp;

Drugs Used:

lenalidomide,

dexamethasone

Quick Link(s):

Regimen Monograph

May 2022

Regimen

DASA

Cancer Type:

Hematologic,

Leukemia - Chronic Myeloid (CML)

Intent: Palliative

Funding:

Exceptional Access Program

daSAtinib - Ph+ CML in the chronic phase, with specific criteria

Exceptional Access Program

daSAtinib - Accelerated phase or blast phase Ph+ CML with documented resistance or intolerance to imatinib, with specific criteria

Drugs Used:

daSATinib

Quick Link(s):

Regimen Monograph

Feb 2025

Regimen

DECI

Cancer Type:

Hematologic,

Myelodysplastic Syndrome (MDS)

Intent: Palliative

Drugs Used:

decitabine (Unfunded)

Quick Link(s):

Regimen Monograph

May 2019

Regimen

DDGP

Cancer Type:

Hematologic,

Lymphoma - T-cell

Intent: Curative

Funding:

New Drug Funding Program

Pegaspargase - Extranodal Natural Killer/T-cell Lymphoma

ODB - General Benefit

dexamethasone

Drugs Used:

Quick Link(s):

Regimen Monograph

Jan 2022

Regimen

DABRTRAM

Cancer Type:

Skin,

Melanoma

Intent: Adjuvant, Curative

Funding:

Exceptional Access Program

daBRAfenib - For the adjuvant treatment of resected Stage III cutaneous melanoma according to clinical criteria

Exceptional Access Program

trametinib - For the adjuvant treatment of resected Stage III cutaneous melanoma according to clinical criteria

Drugs Used:

daBRAFenib,

trametinib

Quick Link(s):

Regimen Monograph

Jun 2021

Regimen

DARODOCE

Cancer Type:

Genitourinary,

Prostate

Intent: Palliative

Funding:

Exceptional Access Program

darolutamide - For the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel

Drugs Used:

DOCEtaxel,

darolutamide

Quick Link(s):

Regimen Monograph

Mar 2024

Regimen

DOCE+PEMB

Cancer Type:

Breast

Intent: Neoadjuvant

Funding:

New Drug Funding Program

Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer

Drugs Used:

pembrolizumab,

DOCEtaxel

Quick Link(s):

Regimen Monograph

Sep 2023

Regimen

DOCE+PERT+TRAS

Cancer Type:

Breast

Intent: Palliative

Funding:

New Drug Funding Program

Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer

New Drug Funding Program

Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

Sep 2022

Regimen

DOCEGEMC

Cancer Type:

Gynecologic,

Uterine Sarcoma,

Sarcoma,

Soft Tissue,

Uterine

Intent: Palliative, Adjuvant

Drugs Used:

gemcitabine,

DOCEtaxel

Quick Link(s):

Regimen Monograph

Dec 2017

Regimen

DOCEPRED

Cancer Type:

Genitourinary,

Prostate

Intent: Palliative

Funding:

ODB - General Benefit

prednisone

Drugs Used:

DOCEtaxel,

prednisone